FHIR Release 3 (STU) R4 Ballot #2 (Mixed Normative/Trial use)

This page is part of the FHIR Specification (v3.0.2: STU 3). (v3.5.0: R4 Ballot #2). The current version which supercedes this version is 5.0.0 . For a full list of available versions, see the Directory of published versions . Page versions: R4 R3

4.3.2.1070 4.4.2.1070 HL7 v3 Code System substanceAdminSubstitution

Vocabulary Work Group   Maturity Level : N/A External Use Context : Any

This code system (http://hl7.org/fhir/v3/substanceAdminSubstitution) (http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution) is defined as part of HL7 v3.

Summary

Defining URL: http://hl7.org/fhir/v3/substanceAdminSubstitution http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution
Version: 2018-08-12
Name: v3.substanceAdminSubstitution
Title: v3 Code System substanceAdminSubstitution
Definition:

Identifies what sort of change is permitted or has occurred between the therapy that was ordered and the therapy that was/will be provided.

OID: 2.16.840.1.113883.5.1070 (for OID based terminology systems)
Source Resource XML / JSON

This Code system is used in the following value sets:

4.3.2.1070.1 4.4.2.1070.1 Code System Content

Release Date: 2016-11-11 2018-08-12

Level Code Display Definition
1 (_ActSubstanceAdminSubstitutionCode) Abstract   Description: Substitution occurred or is permitted with another product that may potentially have different ingredients, but having the same biological and therapeutic effects.
2   E equivalent Description: Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product.
3     EC equivalent composition Description:
Substitution occurred or is permitted with another product that is a:
pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration Examples:
Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin Stearate Pharmaceutical equivalent: Lisonpril for Zestril
4       BC brand composition Description:
Substitution occurred or is permitted between equivalent Brands but not Generics
Examples:
Zestril for Prinivil Coumadin for Jantoven
4       G generic composition Description: Substitution occurred or is permitted between equivalent Generics but not Brands
Examples:
Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp)
3     TE therapeutic alternative Description: Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile.
Examples:
ranitidine for Tagamet
4       TB therapeutic brand Description: Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics
> Examples:
Zantac for Tagamet
4       TG therapeutic generic Description: Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands
> Examples:
Ranitidine for cimetidine
2   F formulary Description: This substitution was performed or is permitted based on formulary guidelines.
2   N none No substitution occurred or is permitted.